Cash on Hand for Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's latest reported cash and short-term investments is $3.82B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingCash on HandSwitch metric
Latest period
$3.82B
YoY change
+60.7%
5Y CAGR
+7.9%
Peak year (2016)
$4.90B
Latest annual
$3.82B
Cash on Hand history chart for Biogen (BIIB) from 1985 to 2025
Cash on Hand history table for Biogen (BIIB) from 1985 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $3.82B | +60.7% | ||
| 2024 | $2.38B | +126.2% | ||
| 2023 | $1.05B | -78.5% | ||
| 2022 | $4.89B | +28.7% | ||
| 2021 | $3.80B | +45.7% | ||
| 2020 | $2.61B | -41.7% | ||
| 2019 | $4.48B | +26.5% | ||
| 2018 | $3.54B | -4.1% | ||
| 2017 | $3.69B | -24.6% | ||
| 2016 | $4.90B | +42.8% | ||
| 2015 | $3.43B | +85.8% | ||
| 2014 | $1.85B | +50.9% | ||
| 2013 | $1.22B | -28.3% | ||
| 2012 | $1.71B | +0.9% | ||
| 2011 | $1.69B | +40.0% | ||
| 2010 | $1.21B | -4.4% | ||
| 2009 | $1.26B | -7.9% | ||
| 2008 | $1.37B | +15.9% | ||
| 2007 | $1.18B | +31.1% | ||
| 2006 | $902.69M | +6.1% | ||
| 2005 | $850.75M | -19.6% | ||
| 2004 | $1.06B | +26.6% | ||
| 2003 | $835.96M | -3.6% | ||
| 2002 | $867.11M | +8.6% | ||
| 2001 | $798.11M | +17.0% | ||
| 2000 | $682.41M | +4.3% | ||
| 1999 | $654.54M | +26.6% | ||
| 1998 | $516.91M | +17.5% | ||
| 1997 | $440.09M | +36.9% | ||
| 1996 | $321.38M | +4.4% | ||
| 1995 | $307.95M | +15.0% | ||
| 1994 | $267.80M | +259.5% | ||
| 1993 | $74.50M | -13.3% | ||
| 1992 | $85.90M | +51.8% | ||
| 1991 | $56.60M | +349.2% | ||
| 1990 | $12.60M | -62.0% | ||
| 1989 | $33.20M | -38.9% | ||
| 1988 | $54.30M | -0.2% | ||
| 1987 | $54.40M | -22.8% | ||
| 1986 | $70.50M | +31.8% | ||
| 1985 | $53.50M | — |
Cash on Hand values are taken from Biogen's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Biogen (BIIB) most recent annual cash and short-term investments stands at $3.82B (2025) – surged 60.7% year-over-year.
Biogen cash and short-term investments has grown for 2 consecutive years, with a +7.9% compound annual growth rate over 2020–2025 (5 years).
Between 2016 and 2025, Biogen cash and short-term investments declined 22.1%, falling from $4.90B to $3.82B.
$4.90B stands as the all-time-high annual cash and short-term investments, posted in 2016, against a low of $12.60M during 1990.
Biogen (BIIB) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $11.85B.
Biogen Cash on Hand by Year
Biogen Cash on Hand 2025: $3.82B
Biogen cash and short-term investments in 2025 was $3.82B, surged 60.7% from 2024.
Biogen Cash on Hand 2024: $2.38B
Biogen cash and short-term investments in 2024 was $2.38B, surged 126.2% from 2023.
Biogen Cash on Hand 2023: $1.05B
Biogen cash and short-term investments in 2023 was $1.05B, plunged 78.5% below 2022.
Biogen Cash on Hand 2022: $4.89B
Biogen cash and short-term investments in 2022 was $4.89B, grew 28.7% from 2021.
Biogen Cash on Hand 2021: $3.80B
Biogen cash and short-term investments in 2021 was $3.80B.
See more financial history for Biogen (BIIB).
Sector peers — Cash on Hand
Companies in the same sector as Biogen, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Biogen's cash and short-term investments?
- Latest reported cash and short-term investments for Biogen (BIIB) is $3.82B (period ending December 31, 2025).
How has Biogen cash and short-term investments changed year-over-year?
- Biogen (BIIB) cash and short-term investments changed +60.7% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen cash and short-term investments?
- Biogen (BIIB) cash and short-term investments compound annual growth rate is +7.9% over the most recent 5 years available.
When did Biogen cash and short-term investments hit its highest annual value?
- Biogen cash and short-term investments reached its highest annual value of $4.90B in 2016.
What was Biogen cash and short-term investments in 2024?
- Biogen (BIIB) cash and short-term investments in 2024 was $2.38B.
What was Biogen cash and short-term investments in 2025?
- Biogen (BIIB) cash and short-term investments in 2025 was $3.82B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.